Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan.

Old world cutaneous leishmaniasis (CL) is caused by Leishmania major and Leishmania tropica, and is endemic to several Asian and Middle-Eastern countries where the rates of infection can be substantial. CL is one of the most common vector-transmitted parasitic infections in Afghanistan. Six cases of CL in Canadian soldiers returning from Afghanistan are reported in the present study. Their lesions did not improve with fluconazole therapy, and the organism demonstrated in vitro resistance. Oral miltefosine seemed effective.

• Publication year

  2008

• Venue

  The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale

• Publication date

  2008-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1155/2008/802710PMID 19436567PMCID PMC2663468
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treating cutaneous leishmaniasis patients in Kabul, Afghanistan: cost-effectiveness of an operational program in a complex emergency setting

  2007cited by this paper
• Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs

  2007cited by this paper
• [Oral miltefosine to treat leishmaniasis].

  2006cited by this paper
• Zoonotic Cutaneous Leishmaniasis, Afghanistan

  2006cited by this paper
• In harm's way: infections in deployed American military forces.

  2006cited by this paper
• Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial.

  2005cited by this paper
• Advances in leishmaniasis.

  2005cited by this paper
• Leishmania tropica in northern Israel: a clinical overview of an emerging focus.

  2005cited by this paper
• Miltefosine for new world cutaneous leishmaniasis.

  2004cited by this paper
• Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India.

  2004cited by this paper
• Update: Cutaneous leishmaniasis in U.S. military personnel--Southwest/Central Asia, 2002-2004.

  2004cited by this paper
• Oral miltefosine for Indian visceral leishmaniasis.

  2002cited by this paper
• Leishmaniasis.

  1999cited by this paper
• Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration.

  1997cited by this paper
• A randomized clinical trial of topical paromomycin versus oral ketoconazole for treating cutaneous leishmaniasis in Turkey

  1997cited by this paper
• Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm.

  1993cited by this paper

• Cutaneous leishmaniasis in Afghanistan

  2025cites this paper
• Tolerability and Safety of Miltefosine for the Treatment of Cutaneous Leishmaniasis

  2024cites this paper
• Anti-leishmanial therapies: overcoming current challenges with emerging therapies

  2024cites this paper
• Case Report: Local Treatment of a Leishmania tropica Infection in a Syrian Child with a Novel Filmogenic Preparation of Pharmaceutical Sodium Chlorite (LeiProtect®).

  2022cites this paper
• Investigation of in vitro Efficacy of Miltefosine on Chronic Cutaneous Leishmaniasis.

  2022cites this paper
• Effectiveness of miltefosine in cutaneous leishmaniasis caused by Leishmania tropica in Pakistan after antimonial treatment failure or contraindications to first line therapy-A retrospective analysis.

  2021cites this paper
• Cutaneous leishmaniasis in refugees from Syria: complex cases in Berlin 2015-2020.

  2020cites this paper
• Overcoming the Challenge; In Vivo Efficacy of Miltefosine for Chronic Cutaneous Leishmaniasis

  2020cites this paper
• Leishmania Immunity: Advancing Immunotherapy and Vaccine Development

  2020cites this paper
• Efficacy and Tolerability of Miltefosine in the Treatment of Cutaneous Leishmaniasis.

  2020cites this paper
• Current and emerging medications for the treatment of leishmaniasis

  2019cites this paper
• [Refractory cutaneous leishmaniasis: Benefit of miltefosine].

  2019cites this paper
• Cutaneous Leishmania tropica in children: report of three imported cases successfully treated with liposomal amphotericin B

  2018cites this paper
• Pathways leading to interleukin-12 production and protective immunity in cutaneous leishmaniasis.

  2016cites this paper
• Leishmaniasis and various immunotherapeutic approaches

  2016cites this paper
• An update on pharmacotherapy for leishmaniasis

  2015cites this paper
• Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations.

  2015cites this paper
• Rapid Healing of Cutaneous Leishmaniasis by High-Frequency Electrocauterization and Hydrogel Wound Care with or without DAC N-055: A Randomized Controlled Phase IIa Trial in Kabul

  2014influential citation
• Therapeutic Options for Old World Cutaneous Leishmaniasis and New World Cutaneous and Mucocutaneous Leishmaniasis

  2013cites this paper
• Clinical pharmacology in leishmaniasis: treatment optimization of a neglected disease

  2013cites this paper
• Leishmaniasis: An Update on a Neglected Tropical Disease

  2013cites this paper
• Genetic Polymorphisms and Drug Susceptibility in Four Isolates of Leishmania tropica Obtained from Canadian Soldiers Returning from Afghanistan

  2012cites this paper
• Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis

  2012cites this paper
• Cutaneous Leishmaniasis in Royal Marines from Oruzgan, Afghanistan

  2012cites this paper
• UvA-DARE ( Digital Academic Repository ) Clinical pharmacology in leishmaniasis : treatment optimization of a neglected disease

  2012cites this paper
• Miltefosine for Old World cutaneous leishmaniasis: An experimental study on Leishmania major infected mice

  2012cites this paper
• A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis.

  2011cites this paper
• Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica

  2011cites this paper
• Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine

  2011cites this paper
• Therapy of vector-borne protozoan infections in nonendemic settings

  2011cites this paper
• Diagnosis and therapy of cutaneous and mucocutaneous Leishmaniasis in Germany

  2011cites this paper
• Leishmaniasis: new insights from an old and neglected disease

  2011cites this paper
• Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan.

  2010cites this paper
• Two cases of Old World cutaneous leishmaniasis in Australian travelers visiting Morocco.

  2010cites this paper
• Exacerbation of Leishmania (Viannia) shawi infection in BALB/c mice after immunization with soluble antigen from amastigote forms

  2010cites this paper